|
1.
|
Clear description of the referenced document:
|
|
|
|
Name:
|
HL7 CDA CD (2017)
|
|
Title:
|
HL7 CDA R2 implementation guide: Privacy consent directives, Release 1
|
|
|
2.
|
Status of approval:
|
|
|
Approved by HL7 as a Normative publication in 2017-01-12.
|
|
3.
|
Justification for the specific reference:
|
|
|
The privacy consent directives in this specification are widely adopted in the industry and used in the H.810 stack. This is an update of the previously used consent directives for trial use (HL7 CDA CD (2011)), initially qualified for the initial H.813 version.
|
|
4.
|
Current information, if any, about IPR issues:
|
|
|
N/A
|
|
5.
|
Other useful information describing the "Quality" of the document:
|
|
|
Approved by HL7 as a Normative publication in 2017-01-12, after several years in trial use (DSTU).
|
|
6.
|
The degree of stability or maturity of the document:
|
|
|
See item 5 above.
|
|
7.
|
Relationship with other existing or emerging documents:
|
|
|
This document replaces [HL7 CDA CD] from 2011-01, HL7 Implementation Guide for Clinical
Document Architecture, Release 2: Consent Directives, Release 1, HL7 Draft Standard for Trial Use.
http://www.hl7.org/documentcenter/public/standards/dstu/CDAR2_IG%20_CONSENTDIR_DSTU_2011JAN.pdf
|
|
8.
|
Any explicit references within that referenced document should also be listed:
|
|
|
1. HL7 Version 3 Domain Analysis Model: Security, Release 1- contains the Harmonized Security and Privacy Domain Analysis Model that specifies the contents of a Privacy Consent Directive document. The full Domain/
Analysis Model publication is available for review and comment on the HL7 DSTU page./
2. ONC S&I Data Segmentation for Privacy Initiative (DS4P) has leveraged the DSTU version of this specification. A Privacy Consent Directive document is required in the Data Segmentation for Privacy Use Cases referenced in/
the Implementation Guide developed for the DS4P Initiative./
3. HL7 Implementation Guide: CDA Release 2 – Continuity of Care Document (CCD) A CDA implementation of ASTM E2369-05 Standard Specification for Continuity of Care Record © (CCR) April 01, 2007 available through/
HL7 ./
4. HL7 Implementation Guide for CDA Release 2 Quality Reporting Document Architecture (QRDA) Draft Standard for Trial Use March 2009. Available at: Quality Reporting Document Architecture (QRDA)/
5. HL7 Implementation Guide for CDA Release 2 CDA for Public Health Case Reports (PHCR) Informative Standard October 2009. Available through HL7 ./
6. HL7 Implementation Guide for CDA Release 2: NHSN Healthcare Associated Infection (HAI) Reports, Release 2 Draft Standard for Trial Use January 2009 Available at: NHSN Healthcare Associated Infection (HAI) Reports/
7. Dolin RH, Alschuler L, Boyer S, Beebe C, Behlen FM, Biron PV, Shabo A, (Editors). HL7 Clinical Document Architecture, Release 2.0. ANSI-approved HL7 Standard; May 2005. Ann Arbor, Mich.: Health Level Seven, Inc./
Available through HL7 or if an HL7 member with the following link: CDA Release 2 Normative Web Edition./
8. LOINC ® : Logical Observation Identifiers Names and Codes, Regenstrief Institute./
9. SNOMED CT ® : SNOMED Clinical Terms SNOMED International Organization./
10.Extensible Markup Language, www.w3.org/XML ./
11. Dolin RH, Alschuler L, Boyer S, Beebe C, Behlen FM, Biron PV, Shabo A., HL7 Clinical Document Architecture, Release 2. J Am Med Inform Assoc. 2006;13:30-39. Available at: http://www.jamia.org/cgi/reprint/13/1/30 ./
12.Using SNOMED CT in HL7 Version 3; Implementation Guide, Release 1.5. Available through HL7 or if an HL7 member with the following link: Using SNOMED CT in HL7 Version 3/
13.OASIS XACML eXtensible Access Control Markup Language is maintained by Organization for the Advancement of Structured Information Standards/
14.Cross-Enterprise Security and Privacy Authorization (XSPA) Profile of Security Assertion Markup Language (SAML) for Healthcare v1.0
|
|
9.
|
Qualification of
HL7:
|
|
|
Health Level 7 meets the qualifying criteria for normative referencing as per Recommendation ITU-T A.5.
|
|
10.
|
Other (for any supplementary information):
|
|
|
N/A
|
